Contemporary management of sinonasal cancer.
BACKGROUND
Sinonasal cancer is a relatively uncommon entity encountered by head and neck oncologists, rhinologists, and skull base surgeons. Recent innovations in surgical and nonsurgical therapeutic modalities raise the question of whether there has been any measurable improvement for treatment outcomes.


METHODS
A retrospective review of data from recent studies that focus on surgery, radiation, and chemotherapy, or combinations thereof, was conducted.


RESULTS
Surgery continues to be the preferred treatment and provides the best results, albeit with an inherent bias based on patient selection. For advanced disease (T4 lesions), the survival rate remains only modest. Complications of treatment, including both surgical and radiation therapy, have been reduced.


CONCLUSIONS
There is a need to improve the efficacy of treatment for this disease. Recommendations for the future direction of therapeutic investigations are outlined.
Robbins
K Thomas
KT
Division of Otolaryngology-Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
Ferlito
Alfio
A
Silver
Carl E
CE
Takes
Robert P
RP
Strojan
Primoz
P
Snyderman
Carl H
CH
de Bree
Remco
R
Haigentz
Missak
M
Langendijk
Johannes A
JA
Rinaldo
Alessandra
A
Shaha
Ashok R
AR
Hanna
Ehab Y
EY
Werner
Jochen A
JA
Suárez
Carlos
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004724:Endoscopy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects; D008207:Lymphatic Metastasis; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000628:therapy*; D010255:Paranasal Sinus Neoplasms / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011788:Quality of Life; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor